Largest biotech by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Amgen leads the 21 biotech ranked by revenue, at PLN 147.8B, ahead of Gilead Sciences (PLN 118.4B) and Biogen (PLN 39.8B). Figures as of 18 Nov 2026, 15:42 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 21
- First
- AmgenPLN 147.8B
- Median
- PLN 4.9B
- Combined market value
- PLN 3.37T
- Countries
- 5
- Not ranked
- 3no revenue on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | PLN 147.8B | PLN 970.6B | PLN 1,794.45 | 2.55% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | PLN 118.4B | PLN 839.3B | PLN 676.63 | 1.17% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | PLN 39.8B | PLN 147.6B | PLN 998.40 | 1.00% down | 49% up | ||
| 4 | argenxARGX · Health Care | PLN 16.7B | PLN 240.2B | PLN 3,819.62 | 0.24% up | 4% up | ||
| 5 | BioNTechBNTX · Health Care | PLN 12.8B | PLN 83.6B | PLN 337.31 | 1.15% down | 16% down | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | PLN 11.5B | PLN 65.8B | PLN 649.77 | 2.62% down | 20% up | ||
| 7 | ExelixisEXEL · Health Care | PLN 9.3B | PLN 67.2B | PLN 275.26 | 0.07% down | 63% up | ||
| 8 | QiagenQGEN · Health Care | PLN 8.4B | PLN 41.1B | PLN 199.24 | 0.41% down | 12% up | ||
| 9 | ModernaMRNA · Health Care | PLN 7.8B | PLN 327.4B | PLN 809.10 | 2.71% down | 755% up | ||
| 10 | Halozyme TherapeuticsHALO · Health Care | PLN 5.6B | PLN 44.2B | PLN 387.62 | 0.44% up | 37% up | ||
| 11 | Bio-TechneTECH · Health Care | PLN 4.9B | PLN 45.9B | PLN 292.39 | 0.11% up | 26% up | ||
| 12 | RepligenRGEN · Health Care | PLN 3B | PLN 43.7B | PLN 682.85 | 4.70% up | 5% up | ||
| 13 | Krystal BiotechKRYS · Health Care | PLN 1.6B | PLN 36.2B | PLN 1,222.01 | 1.79% up | 46% up | ||
| 14 | Twist BioscienceTWST · Health Care | PLN 1.5B | PLN 31.1B | PLN 455.82 | 1.21% up | 340% up | ||
| 15 | Adaptive BiotechnologiesADPT · Health Care | PLN 1.1B | PLN 18.5B | PLN 114.37 | 0.18% down | 88% up | ||
| 16 | ImmunityBioIBRX · Health Care | PLN 455.6M | PLN 28.4B | PLN 26.72 | 6.16% up | 193% up | ||
| 17 | Kymera TherapeuticsKYMR · Health Care | PLN 157.7M | PLN 41.5B | PLN 486.68 | 0.41% down | 87% up | ||
| 18 | CG OncologyCGON · Health Care | PLN 16.2M | PLN 28.6B | PLN 320.34 | 0.91% up | 85% up | ||
| 19 | CRISPR TherapeuticsCRSP · Health Care | PLN 14.1M | PLN 16B | PLN 165.18 | 2.30% up | 21% down | ||
| 20 | Revolution MedicinesRVMD · Health Care | PLN 0 | PLN 138.1B | PLN 638.47 | 2.41% down | 131% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | PLN 0 | PLN 23B | PLN 188.74 | 4.11% up | 14% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0213 PLN). 3 companies have no revenue on file and are not ranked here.
Questions and answers
Which biotech rank first by revenue?
Amgen (PLN 147.8B), Gilead Sciences (PLN 118.4B) and Biogen (PLN 39.8B) are the top three of the 21 biotech ranked by revenue as of 18 Nov 2026, 15:42 UTC.
How many biotech are in this ranking?
21 are ranked by revenue. 3 more have no revenue on file and are left out rather than ranked at zero.
What are these biotech worth together?
The 21 biotech ranked by revenue have a combined market value of PLN 3.37T as of 18 Nov 2026, 15:42 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech by revenue”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.